Mitsubishi UFJ Asset Management Co. Ltd. Raises Stock Position in Sanofi (NASDAQ:SNY)

Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Sanofi (NASDAQ:SNY) by 6.7% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,032 shares of the company’s stock after buying an additional 253 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Sanofi were worth $224,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Accent Capital Management LLC purchased a new position in shares of Sanofi in the 1st quarter worth $29,000. Eastern Bank boosted its stake in shares of Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company’s stock worth $30,000 after purchasing an additional 300 shares during the period. Golden State Wealth Management LLC boosted its stake in shares of Sanofi by 619.3% during the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company’s stock worth $35,000 after purchasing an additional 545 shares during the period. Bessemer Group Inc. boosted its stake in shares of Sanofi by 59.8% during the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company’s stock worth $32,000 after purchasing an additional 242 shares during the period. Finally, Brentview Investment Management LLC purchased a new position in shares of Sanofi during the 1st quarter worth about $42,000. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Trading Up 0.6%

Shares of SNY opened at $49.04 on Friday. Sanofi has a 1-year low of $44.73 and a 1-year high of $60.12. The company has a 50-day moving average of $48.58 and a 200 day moving average of $51.85. The firm has a market capitalization of $120.42 billion, a price-to-earnings ratio of 11.79, a PEG ratio of 1.16 and a beta of 0.48. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The business had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. During the same quarter in the prior year, the firm posted $1.73 EPS. The company’s revenue for the quarter was down 7.0% compared to the same quarter last year. On average, research analysts expect that Sanofi will post 4.36 EPS for the current year.

Analyst Ratings Changes

SNY has been the subject of a number of recent analyst reports. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Morgan Stanley set a $56.00 price target on shares of Sanofi in a research note on Monday, June 2nd. Barclays reaffirmed an “overweight” rating on shares of Sanofi in a research note on Wednesday, July 2nd. Guggenheim reaffirmed a “buy” rating on shares of Sanofi in a research note on Tuesday, June 3rd. Finally, JPMorgan Chase & Co. upgraded shares of Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, Sanofi currently has a consensus rating of “Buy” and an average target price of $62.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.